Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1
about
Lung function abnormalities in HIV-infected adults and childrenPredictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort.Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South AfricaEnsuring the involvement of children in the evaluation of new tuberculosis treatment regimensToxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in EthiopiaValidation of 2006 WHO prediction scores for true HIV infection in children less than 18 months with a positive serological HIV testDeterminants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART eraGuidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerImpact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents.The second generation of HIV-1 vertically exposed infants: a case series from the Italian Register for paediatric HIV infectionEarly severe HIV disease precedes early antiretroviral therapy in infants: Are we too late?A comparison of adherence assessment methods utilized in the United States: perspectives of researchers, HIV-infected children, and their caregivers.Association of site-specific and participant-specific factors with retention of children in a long-term pediatric HIV cohort study.Clinical evaluation of a dried blood spot assay for atazanavirNeurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.Imaging lung manifestations of HIV/AIDS.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theAssessing medication adherence of perinatally HIV-infected children using caregiver interviews.Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART).Factors associated with HIV-status disclosure to HIV-infected children receiving care at Kilimanjaro Christian Medical Centre in Moshi, Tanzania.Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countriesSingle-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.The influence of substance use, social sexual environment, psychosocial factors, and partner characteristics on high-risk sexual behavior among young Black and Latino men who have sex with men living with HIV: A qualitative studyMonitoring Antiretroviral Therapy in HIV-Infected Children in Resource-Limited Countries: A Tale of Two EpidemicsCD4/CD8 T-cell ratio predicts HIV infection in infants: the National Heart, Lung, and Blood Institute P2C2 Study.PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS.Assessment of thymic activity in human immunodeficiency virus-negative and -positive adolescents by real-time PCR quantitation of T-cell receptor rearrangement excision circles.Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children.Medication adherence in children and adolescents with HIV infection: associations with behavioral impairment.Cohort profile: the TREAT Asia pediatric HIV observational database.Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes.Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda.Disclosure of their status to youth with human immunodeficiency virus infection in the Dominican Republic: a mixed-methods studyCharacteristics of HIV infected adolescents in Latin America: results from the NISDI pediatric study.Comprehensive screening reveals strong and broadly directed human immunodeficiency virus type 1-specific CD8 responses in perinatally infected children.HIV-Care Outcome in Saudi Arabia; a Longitudinal Cohort.
P2860
Q26863389-F84C2156-3C42-4F7F-A3CC-74A35068FCC9Q30494934-B94D0E87-A3E8-4EE2-B457-91B798A8C4ACQ33279183-CB84A98C-2FEF-4C2F-943C-B752FFC4A828Q33361748-752A8EBD-9A98-4BBD-81A3-9A2C59B70778Q33381965-F62F5F56-2689-4AA9-8EF0-A6A3F67D32CDQ33390518-CBDD9337-CAAC-4CB7-A729-9F6727AE0C51Q33434524-00E696A3-1E31-44C9-8605-99C4840A50B7Q33553629-FA945F7C-1620-48EC-B2FC-C33CAEDBE08BQ33572442-31CB25F6-246C-4815-B118-1629CDE8E854Q33650105-B51CE840-1968-49A7-89B2-74A6CE19C6B9Q33650149-9CFD3957-A703-462F-91E0-57CD8D67A358Q33673661-EF0218E6-D8B1-4682-A9B1-12659E179FFCQ33750539-E03C4036-1833-4C95-B8B3-E57BB74FDB67Q33810883-FE4D87EC-351E-4156-884B-AC1C7AC3FFE7Q33822738-F98BC15C-261C-4E22-939F-BD11551D152DQ34150893-9903D245-30B9-4884-A751-68B8F5619060Q34181048-74EC9FBE-2623-4D25-A341-D9D8368F1EE5Q34195916-BA08978A-3026-4DEC-8849-7F371B49D64EQ34212799-2E1590D8-37CC-43E2-9D11-982FB79BF876Q34242255-11072F2B-282F-47A0-9E4E-52222E8C872AQ34312439-6A539C41-5D4F-4050-84FD-76A8F647675EQ34431685-5A10DFB3-FB4E-481F-99BC-E79235B12691Q34443184-78FE6372-7707-43BC-9BE2-EC9E3A8C38ABQ34513045-DEBA9C3A-BA8E-4703-9D0D-DE5E83CB11AFQ34544211-DB3C5D91-9238-4C82-9485-D5AA500214A3Q34622948-D31534E8-4B6C-42C0-ABF7-12BE5FC159AEQ34627300-2174E517-5A67-42DC-85E1-6D3647413BD1Q34734797-CD510832-2E99-4815-BBD9-40133C9F3F6EQ34737680-9CC06B6B-A01C-455C-8C83-92736C00D857Q34760550-04A3D7D2-C37F-4591-B486-975FDD7C17D6Q34779227-722AA1A9-45AD-453A-AAF2-ACA1C03B47FAQ34952722-CEA7EF58-28F3-4A69-884C-381EE9B8DB7EQ35006958-68C89559-C9BE-465F-9736-CFDD29EF5119Q35020908-A933B5AA-4120-4259-8941-9990489AE0C6Q35074791-83B04CE9-F44E-41E0-BED7-5A7F28B51FF9Q35107571-968529B8-5F48-4579-BE44-D887539D0687Q35130681-39C6912F-6B4D-424B-B1EC-5099A47726FDQ35133104-F0EC65F4-5ECC-4FCB-BDAA-B646FC719FCDQ35149075-212B9723-385D-4266-8FCA-0E13DC948430Q35149265-D55DB817-C6DE-4ABD-B130-0B4AAB854F3E
P2860
Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1
description
article
@en
im November 2001 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2001
@uk
name
Effect of Combination Therapy ...... dolescents Infected with HIV-1
@en
Effect of Combination Therapy ...... dolescents Infected with HIV-1
@nl
type
label
Effect of Combination Therapy ...... dolescents Infected with HIV-1
@en
Effect of Combination Therapy ...... dolescents Infected with HIV-1
@nl
prefLabel
Effect of Combination Therapy ...... dolescents Infected with HIV-1
@en
Effect of Combination Therapy ...... dolescents Infected with HIV-1
@nl
P2093
P356
P1476
Effect of combination therapy ...... dolescents infected with HIV-1
@en
P2093
G M Johnson
Pediatric AIDS Clinical Trials Group Protocol 219 Team
S L Gortmaker
W M Dankner
P304
P356
10.1056/NEJMOA011157
P407
P577
2001-11-01T00:00:00Z